The majority of breast cancers with over expressed or activated Src also over express one of the HER receptors [16,19], and in HER2-positive breast cancer, activated Src correlates with HER2 positivity and poor prognosis [20]. This evidence concerns the gene ERBB2 and breast carcinoma.